{"id":"cesamet-nabilone","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Dizziness"},{"rate":"25-50","effect":"Drowsiness"},{"rate":"10-25","effect":"Euphoria"},{"rate":"10-25","effect":"Dry mouth"},{"rate":"5-15","effect":"Ataxia"},{"rate":"5-15","effect":"Vertigo"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nabilone acts as a partial agonist at CB1 and CB2 cannabinoid receptors, primarily in the brain's chemoreceptor trigger zone and vomiting center. By activating these receptors, it suppresses the neural signals that trigger nausea and emesis, making it effective for chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV).","oneSentence":"Nabilone is a synthetic cannabinoid that mimics THC and binds to cannabinoid receptors in the central nervous system to reduce nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:21.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Post-operative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT00418678","phase":"PHASE4","title":"A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting","status":"TERMINATED","sponsor":"Veeda Oncology","startDate":"2006-08","conditions":"Nausea and Vomiting","enrollment":16},{"nctId":"NCT00380913","phase":"PHASE4","title":"Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"NEMA Research, Inc.","startDate":"2006-09","conditions":"Diabetic Neuropathies","enrollment":23},{"nctId":"NCT00380965","phase":"PHASE4","title":"Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy","status":"COMPLETED","sponsor":"NEMA Research, Inc.","startDate":"2006-10","conditions":"Peripheral Neuropathy, Antineoplastic Combined Chemotherapy Protocols","enrollment":23},{"nctId":"NCT00381264","phase":"PHASE4","title":"Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"NEMA Research, Inc.","startDate":"2006-09","conditions":"Multiple Sclerosis","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":400,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cesamet™ (nabilone)","genericName":"Cesamet™ (nabilone)","companyName":"NEMA Research, Inc.","companyId":"nema-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nabilone is a synthetic cannabinoid that mimics THC and binds to cannabinoid receptors in the central nervous system to reduce nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}